RE:RE:RE:RE:AasldI think both company and any interested partner would only move after results which would show promise, thus move the share a bunch higher. We'll get some kind of read on cancer in 2021 as survival or tumor fighting capacity would have to be released one way or the other and something in 2022 on NASH. Between here and there, it should be clear to them if the cheapest financing is via market or via partnership that involves royalties, worldwide sales staff and milestone payments. It should be easy to see which is the better option. Maybe even both --if you still want a few more years of independence you could bring in an industry partner as a keystone investor in a deal. Best of both worlds -- make them pay the market multiple, keep them at bay, and use their sales staff to help you. Then if you reach the commercial end with either, you can watch a bidding war erupt, like for Immunomedics!
SPCEO1 wrote: This is one of the problems with the low share price. We know there is a good chance things could turn out to be very, very, very interesting in both cancer and NASH, but that view has not been broadly accepted. The resulting low share price means the company has been cash poor (relative to most successful US biotech stocks) and that likely means there is a reluctance to spend on anything extra. I think the company has likely moved past the poverty mentality it once had but not too far beyond that unfortunately. If they can effectively market the stock, like so many other companies have been able to do, the share price will reflect the opportunities and raising money to do as thorough a job as possible to exploit these opportunities would be easy and relatively painless to legacy shareholders like ourselves. But as thibgs currently stand, we have a small medical staff and therefore limited medical resources. Christian is doing amazing things with such limited resources but he has to be limited.
If TH pulls off even one of the two primary R&D gambits, the company will almost certainly end up being acquired by a big pharma company. If it soehow ends up with legit potential products in both NASH and cancer, then there will be a significant bidding war for TH in the not too distant future as big pharma will not let those opportunities be slow walked to fruition by an understaffed medical team.
The current share price is just plain stupid. No one knows if TH will be successful in both NASH and cancer but they sure seem to have a very legit shot at both. Can you imagine how valuable TH would be to big pharma with legit shots in both NASH and cancer? It would get bought out and we would will likely lose a lot of potential value in the process but we would still likely do very, very well.
qwerty22 wrote: At some point eventually big pharma will buy all the leading Nash drug you'd expect. And ultimately what matters is the ability of these drugs to impact not just surrogate endpoints but the long term endpoints like end stage liver diseases and CV events. Pharma bucks will be purchasing drugs on what they can show about those long term outcomes because that's what gives the drug a long life. Yes they need to get the Ph3 done but I hope they don't just restrict themselves to that, I hope they get creative and flesh out the bigger issues. I hope Grinspoon's brain is whirring and he can nudge them to what he thinks will be clinically valuable. It'll never happen but I'd love to have Grinspoon as (part-time) Chief Scientific Officer driving the research.
SPCEO1 wrote: I think I have mentioned it before but my uneducated view is that, in the end, Egrifta will be shown to be useful in many other ways than just helping with NASH and CV benefits are at the top of my list for additional benefits. We are a long way from knowing anything about that, however, but it just makes sense to me that this will be the case.